Abstract: Methods for applying injectable fillers are provided. In some embodiments, the methods can extend effectiveness of the injectable filler. In some embodiments, the methods can provide for an elevated level of effectiveness of the injectable filler. In some embodiments, the methods can prolong the effectiveness of the injectable filler.

Abstract: Compositions, methods and kits to be used as a lubricant and for treatment of a cavity pathology including joint pathology are provided. The composition comprises therapeutically effective amounts of at least one bioactive agent, such as magnesium compound, at least one lubricating agent, such as hyaluronic acid, and at least one cell membrane repairing agent, such as polyethylene glycol. The components of these compositions may be administered by a direct application, an application through a cannula, an intra-articular injection, as a flush fluid during an arthroscopy of the affected area, as a post-arthroscopy injection, or as part of a lavage of the area affected by the intra-articular pathology. In addition, the composition of the present invention may be administered to the patient from a pump or a depot.

Abstract: A dressing and method for treating high-tension wounds. First and second layers of a 1-butyl cyanoacrylate 16 adhesive are applied to a short, high-tension wound, with the first and second layers covering the wound and extending to at least about 2.5 mm (0.0984 in.) from each side of the wound. The first layer is allowed to set and polymerize before the second layer of 1-butyl cyanoacrylate is applied. The second layer extends at least about 2.5 mm (0.0984 in.) beyond each edge of the first layer. In the case of a long, high-tension wound, a third layer is applied after the first and second layers are allowed to set and polymerize. The third layer is at least about 2.5 mm (0.0984 in.) wide and is substantially perpendicular to the first and second layers. The third layer may occur intermittently every 2.5 cm (0.984 in.) over the length of the wound, and preferably extends at least about 5 mm (0.197 in.) beyond the edge of the first layer.

Abstract: The present invention relates to the treatment of gastrointestinal and/or cancer, and a method of weight gain, via the ingestion of polymeric compositions in humans, animals or birds in need of said treatment. The invention provides methods for the treatment of cancer, the treatment and/or prevention of gastrointestinal disease and/or infection and/or diarrhea, and a method for increasing weight gain in humans, animals or birds comprising administering to said humans, animals or birds an effective amount of a pharmaceutical or veterinary composition, or feed additive, comprising an effective amount of a polymer and/or copolymer, having the repeating polymeric unit (I), wherein R is H or alkyl, usually C1 to C4, or this unit in hydrated, hemiacetal or acetal form, together with a pharmaceutically or veterinarally acceptable carrier, diluent, adjuvant, excipient and/or controlled release system.

Abstract: The invention at hand concerns hydrophobic polymer surfaces, in particular superhydrophobic polymer surfaces, comprising at least one homo- or copolymer, which comprises at least one side chain with at least one fluoro-substituted aryl group. Furthermore, the invention at hand concerns a method for the production of polymer surfaces of this type, their use and polymers of the general formula I: wherein n is an integer between 10 and 4,500, preferably between 20 and 2,200 and particularly preferably between 100 and 670.

Abstract: The invention relates to self-stabilized dispersions of polymer particles in a non-aqueous non-silicone medium, and to a process for preparing the said polymers. The invention also relates to cosmetic or pharmaceutical compositions comprising the said polymer particle dispersions.

Abstract: This invention relates to a method comprising contacting a microorganism and/or an infectious agent with an effective amount of a polymer composition to reduce or eliminate the reproductivity, metabolism, growth and/or pathogenicity of the microorganism and/or infectious agent, the polymer composition comprising water, a water-soluble film forming polymer, a chelating agent, and a surfactant.

Abstract: The present application relates to a film forming composition for application to mammalian skin, which composition comprises at least one polyurethane based polymer together with at least one acrylate based polymer. The film forming composition provides effective skin coating with good adhesion to the skin, and may be used as a skin protector or a wound dressing.

Abstract: The invention relates in particular to the cosmetic use of a composition containing, in a physiologically acceptable medium, an effective amount of at least one mosaic-effect tensing agent for improving the thickness of the skin and/or promoting the radiance of the complexion. The invention also relates to the cosmetic use, in a composition containing a physiologically acceptable medium, of an effective amount of at least one mosaic-effect tensing agent as an agent intended to improve the firmness and/or elasticity and/or tonicity of the skin. The invention likewise relates to a cosmetic method of treatment of dull and/or poorly defined complexion that comprises the topical application of a composition comprising at least one mosaic-effect tensing agent to people who have a dull and/or poorly defined complexion. Mosaic-effect agents of this kind are selected in particular from (i) mineral tensing agents and (ii) tensing polymers.

Abstract: This invention relates to a method for preparing dispersions of solid particles, especially pigments, metal oxides and mineral fillers in organic media, to dispersing compositions used in this method and to dispersions containing these dispersion compositions. The dispersing compositions include an oil soluble surfactant selected from the group consisting of phospholipids, alkyl acids, nonionic surfactants having an HLB less than 10, and mixtures thereof; either an anhydride based polymer selected from the group consisting of polyalkene succinic anhydrides; maleinized polyisoprene; maleinized polybutadiene; maleinized copolymers of isoprene and butadiene; copolymers of styrene and maleic anhydride; derivatives formed by reaction of the anhydride group of the anhydride based polymer with one or more of water, amines, alcohols, and polyols; and mixtures thereof; or a mixture of the said anhydride based polymer with polyhydroxystearic acid; and optionally a liquid oil carrier.

Abstract: The present invention relates to copolymers which comprise ethyl methacrylate, at least one ?,?-ethylenically unsaturated amide group-containing compound and at least one monoethylenically unsaturated carboxylic acid in copolymerized form, to cosmetic and pharmaceutical compositions which comprise at least one such copolymer, and to the use of these copolymers.

Abstract: Antimicrobial compositions having a rapid antiviral and antibacterial effectiveness, and a persistent antiviral effectiveness, are disclosed. The antimicrobial compositions contain (a) a disinfecting alcohol, (b) an organic acid, and (c) water, wherein the composition has a pH of about 5 or less.

Abstract: The present invention relates to lotion compositions comprised on a body facing surface of an absorbent article such as a diaper, training pants or adult incontinence product. The lotion composition reduces the adherence of feces or menses to the human skin. The lotion composition comprises at least two compounds wherein one first compound is liquid at 25° C. and at least one second component which is solid at 25° C. An effective amount of the lotion composition is comprised on a body facing surface of an absorbent article which is intended to be worn by a wearer.

Abstract: The present invention provides a non-liquid biomaterial that may be used as a surgical sealant, a suture support, a blood flow controller, an adhesion reducing agent, an adhesion preventing agent, a tissue support, a tissue filler, a wound dressing or a combination thereof. The non-liquid biomaterial may comprise a blood derived material such as plasma, platelet poor plasma, platelet rich plasma or a material derived from blood containing tissue aspirate, such as bone marrow aspirate, a protein binding agent and a polymerizing agent. Methods for making and using the non-liquid biomaterial are also provided.

Abstract: A molecular sealant comprising a therapeutically effective amount of a poloxamer capable of sealing a cell or tissue from leaks. A method of treating tissue leakages by applying the above sealant to the tissue or cell in need of treatment. A composition for treating cellular leakages comprising a poloxamer capable of sealing a cell or tissue from leaks in a pharmaceutically acceptable carrier.

Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.

Abstract: The present invention relates to a method for treating a subject for a condition or inflammation associated with oedema, excess body fluids or oedema and excess body fluids, or for treating a subject for an abscess, boil, blister or cyst. The method comprises applying to the skin surface covering a body part or region affected by said condition, inflammation, abscess, boil, blister or cyst a composition capable of transdermally attracting fluids from the body part or region or its proximity, wherein said composition comprises at least one adsorptive or absorptive agent, and leaving said composition in contact with the skin for sufficient time to allow said composition to transdermally absorb or adsorb at least a portion of the body fluids from said body part or region. The present invention also relates to compositions for absorbing or adsorbing fluids from a body part or region, and which are capable of transdermally attracting fluids from body parts or regions or their proximity.

Abstract: The present invention relates to a substrate having one or more antimicrobial or antistatic properties. Such properties are imparted by applying a coating or film formed from a cationically-charged polymer composition. The polymer composition includes a noncationic ethylenically unsaturated monomer and an ethylenically unsaturated monomer capable of providing a cationic charge to the polymer composition. Optionally, the polymer composition includes a steric stabilization component incorporated into the cationically-charged polymer composition. The present invention also relates to a personal care product and polymeric material comprising a base polymer blended with the above cationically-charged polymer composition.

Abstract: The present invention relates to injectable compositions comprising biocompatible, swellable, substantially hydrophilic, non-toxic and substantially spherical polymeric material carriers which are capable of efficiently delivering bioactive therapeutic factor(s) for use in embolization drug therapy. The present invention further relates to methods of embolization gene therapy, particularly for the treatment of angiogenic and non-angiogenic-dependent diseases, using the injectable compositions.

Abstract: A cross-linked material of polylactic acid produced by preparing a polylactic acid composition by mixing polylactic acid with at least a plasticizer containing either a rosin derivative or a dicarboxylic acid derivative and/or a glycerin derivative and cross-linking monomer, and kneading the resulting mixture; preparing a polylactic acid molded product by molding the composition into a desired shape; and then cross-linking the molded product by irradiation of ionizing radiation.

Abstract: Disclosed herein is a process to produce a film comprising poly(vinyl alcohol), wherein the poly (vinyl alcohol) solution has been purified utilizing an ion exchange resin. An approximate 50 micrometer thick film produced from the purified aqueous poly(vinyl alcohol) solution has an APHA color value of 50 or less after the film has been heated at 150° C. for 60 minutes.

Abstract: A pro-angiogenic porous polymer scaffold is disclosed. The polymer has at least 20 mol-% monomeric subunits containing acidic functional groups, and has a porosity of at least 40%. The pores in the scaffold are interconnected. A method of making such a scaffold using a novel adaptation to the traditional solvent casting/particulate leaching technique is also disclosed. The scaffold may be used for tissue regeneration.

Abstract: A method for treating a neoplastic disorder in a subject includes administering to the neoplastic cells a neoplastic cell-sensitizing composition including a poly(ethylene oxide)-poly(propylene oxide) copolymer. The poly(ethylene oxide)-poly(propylene oxide) copolymer can sensitize the neoplastic cells to hyperthermia. Energy can be applied to the neoplastic cells to heat and ablate the cells.

Abstract: The present invention is directed to a method of making up keratinous substrates involving applying onto the keratinous substrate a composition containing a) a block copolymer, b) a tackifier, c) an alkyl silsesquioxane wax, d) a liquid fatty phase, and e) optionally, a colorant.

Abstract: A process for covalently attaching an antimicrobial coating to a polymeric surface. The process comprises contacting the surface of the polymer with a plasma having reactive nitrogen compounds to provide a plasma-treated surface with —NHR groups, wherein R is hydrogen, hydroxyl or C1-2alkyl, reacting the —NHR groups with a surface linking agent, and attaching an amine-containing polymer to the linking agent to form the antimicrobial coating. The surface linking agent is selected from the group consisting of dihaloalkyl, a dihaloalkenyl, and a dihalomethylaryl. The invention is also directed to a contact lens case or a contact lens with an antimicrobial coating.

Abstract: Methods and compositions effective for at least a week for prevention of microbial colony growth on a surface, for example an inanimate surface, where the surface is covered with a dry or substantially dry film formed from a composition comprising a polyvinyl alcohol and a quaternary ammonium compound. The film may be formed in situ by coating the surface with a solution or emulsion comprising a polyvinyl alcohol and a quaternary ammonium compound and then causing or allowing it to dry or substantially dry.

Abstract: This invention relates to a stabilized honey bee pheromone and methods of stabilizing the honey bee brood pheromone, thereby enabling the production and sustained use of commercial products based on that pheromone. The stabilized pheromone can be used to manipulate the behavior and improve the performance of worker honey bees, resulting in overall increased vigor of the hive. The pheromone composition comprises two or more of ethyl linoleate, ethyl linolenate, ethyl oleate, ethyl palmitate, ethyl stearate, methyl linoleate, methyl linolenate, methyl oleate, methyl palmitate and methyl stearate and an antioxidant.

Abstract: Provided are compositions comprising a low molecular weight, non-crosslinked, linear acrylic copolymer and at least one surfactant selected from the group consisting of anionic surfactants, amphoteric surfactants, and combinations of two or more thereof, and methods of using such compositions.

Abstract: The present invention provides methods of treating heart failure and improving renal function, and/or preventing the advancement of heart failure into advanced stages, and methods of counteracting ischemia due to a myocardial infarction by providing improved methods of administering a therapeutically effective amount CGRP as a controlled release formulation. The therapies can be administered on an outpatient or inpatient basis and can further be used as maintenance therapies.

Abstract: Biomedical uses of amphiphilic macromolecules include the use of such macromolecules in the form of nanoparticle formulations for the sequestration and/or removal of LDL, and for the treatment and prevention of atherosclerosis and atherosclerotic development. The invention also provides the use of amphiphilic macromolecule encapsulates for treating diseases including cancer and inflammation, as well as targeted amphiphilic macromolecules and their use in therapy.

Abstract: The hair wax product for treating or setting up a human hairstyle has a composition containing more than 20% by weight of one or more waxy polyethylene glycol, which is solid at at 25° C., and at least one additive substance that prevents crystallization of the waxy solid polyethylene glycol. This additive substance preferably is a hydrophobic wax, a hydrophobic soft waxy material or hydrophobic oil and is contained in the product in an amount of more than 5% by weight. Preferred embodiments of the waxy product can contain an emulsifier and/or an additional polyethylene glycol, which is liquid at 25° C.

Abstract: The present invention is directed to medical devices and pharmaceutical compositions containing a synthetic, bioabsorbable, biocompatible liquid polymer that is the reaction product of a polybasic acid or derivative thereof, a polyol and a fatty acid, the liquid polymer having a melting point less than about 40° C., as determined by differential scanning calorimetry.

Abstract: Dispersion concentrates are claimed which consist of: I) 10-80% by weight of a crosslinked copolymer obtained by polymerization of 1 to 50% by weight of a cyclic N-vinylcarboxamide and 49.99 to 98.99 by weight of acryloyldimethyltauric acid, II) 20-90% by weight of a phase selected from the group consisting of an emulsifier, an oil phase, and mixtures thereof, and III) up to 30% weight water based on the total weight of the stable dispersion concentrate. The stable dispersion concentrate is useful in preparing cosmetic, pharmaceutical, and dermatological compositions.

Abstract: The present invention relates to a novel reactive medical substance having the bone restoration function, comprising a particular methacrylic acid ester, polymer and osteogenic factor. The reactive medical substance of the present invention has a mechanical strength which is increased by a reaction and is used in a living body for a long period of time. The osteoinduction-assistance composition having the bone restoration function of the present invention is characterized in that the composition maintains suitable elasticity, and can be easily formed with scissors or a sharp blade upon use. The reactive medical substance of the present invention comprises a mixture of a methacrylic acid ester, a polymer and a biological absorbing material, and can regenerate a mocosa, form a regenerated epithelium, and stabilize a transplanted piece.

Abstract: The invention is directed to a copolymer comprising at least three types of monomeric units, said three types of monomeric units comprising: a temperature-sensitive unit, a hydrophilic unit, and a hydrophobic unit comprising at least one pH-sensitive moiety; wherein said hydrophobic monomeric unit is derived from a copolymerisable unsaturated fatty acid.

Abstract: In one aspect, the invention is directed to a biocidal composition, comprising a mixture of (a) a substantially oxidation-resistant thermoplastic polymer having a melting point of about 60° C. to about 100° C.; and (b) a composition for releasing chlorine dioxide gas upon exposure to moisture. In another aspect, the invention provides a polymeric matrix comprising the biocidal composition and having a moisture vapor transmission capability of about 100 to about 1000 grams per 24 hours per square meter per mil of thickness. The invention further provides a manufactured article comprising the biocidal composition, for example manufactured by extrusion, injection molding or blow molding.

Abstract: The invention relates to a method for treating Syndrome X, or inhibiting the onset of symptoms of Syndrome X in a patient, and includes administering a therapeutically effective amount of a salt of at least one alkylated and cross-linked polymer, or a copolymer thereof, the polymer salt formed as a product of the reaction of one or more polymers, or salts and copolymers thereof, having a repeat unit that is essentially: where n is a positive integer and each R, independently, is H or a C1–C8 alkyl group; at least one aliphatic alkylating agent; and a cross-linking agent. Long term administration of the cross-linked polyamine salts of the invention increases HDL levels and decreases LDL levels in patients. The invention also provides for administration of the polymer salt colesevelam, in combination with an HMG-CoA reductase inhibitor; the combined administration is effective in further lowering serum total-cholesterol and LDL-cholesterol levels beyond that achieved by either agent alone.

Abstract: Multifunctional biocompatible hydrophilic gel contains, in % (w/w), acrylamide—1.95-8.0, methacrylamide—0.54-3.0, 2-hydroxyethyl methacrylate—0.003-0.4, N,N?-methylene-bis-acrylamide—0.006-0.6 and water—q.s. to 100. The hydrophilic gel is produced by co-polymerization of the above mentioned monomers in water medium in the presence of a peroxide initiator of polymerization in three stages which include (1) incubation of the reaction mixture at 20-30° C. for 12-24 hours, (2) exposure to ?-radiation at a dose of 0.4-1.0×106 rads, and (3) incubation at a temperature of 100-130° C. and pressure of 0-1.2 atm. for 20-40 minutes.

Abstract: Amine polymers, particularly aliphatic amine polymers, are useful in the treatment and prevention of bone disease and in methods for promoting bone formation. Sevelemer, polyallylamine crosslinked with epichlorohydrin, which is sold under the tradename Renagel®, is the preferred polymer used in the invention.

Abstract: A surface on which adsorption of protein (e.g., BSA) is markedly suppressed is provided, by contacting solutions of polymers whose chief component is poly(ethylene oxide) having binding sites to sensor surfaces with biosensor surfaces plural times to link the polymers.

Abstract: In one aspect, the invention provides methods for forming a photopatterned hydrogel. In some embodiments, the methods comprise the step of exposing a solution comprising a monomer, a crosslinking agent, and a photoinitiator to a pattern of light comprising a first and a second light intensity for a period of time and under suitable conditions for the first light intensity to induce essentially complete conversion of polymerizable groups on the monomer and the crosslinking agent to form a patterned hydrogel, and for the second light intensity to induce partial conversion of the polymerizable groups on the monomer and the crosslinking agent to form partially polymerized polymers that remain soluble. In some embodiments, the first light intensity is lower than the second light intensity. In another aspect, the invention provides methods for forming porous, photopatterned hydrogels.

Abstract: Polymers containing amino acid and/or polypeptide moieties in their backbones or pendant to their backbones are made by metathesis. A method of making an amino acid or polypeptide containing polymer includes the steps of: providing a amino acid, amino alcohol, or polypeptide-containing monomer; forming a reaction mixture by contacting the monomer with an agent capable of catalyzing the polymerization of the monomer into a polymer; and placing the reaction mixture under conditions that result in the formation of the polymer in reaction mixture.

Abstract: A dental composite material that comprises a polyhedral oligomeric silsesquioxane is disclosed. The dental composite material is useful for a variety of dental materials, treatments, and restorative functions including crown and bridge materials, fillings, adhesives, sealants, luting agents or cements, denture base materials, orthodontic materials and sealants, and other dental restorative materials.

Abstract: A reagent and related method for use in passivating a biomaterial surface, the reagent including a latent reactive group and a bifunctional aliphatic acid (e.g., fatty acid), in combination with a spacer group linking the latent reactive group to the aliphatic acid in a manner that preserves the desired function of each group. Once bound to the surface, via the latent reactive group, the reagent presents the aliphatic acid to the physiological environment, in vivo, in a manner (e.g., concentration and orientation) sufficient to hold and orient albumin.

Abstract: The hair styling stick contains from 30 to 55 percent by weight of one or more polyethylene glycols with a molecular weight of from 2500 to 5000 g/mol; and from 40 to 70 percent by weight of at least one other polyethylene glycol with a molecular weight of from 570 to 800 g/mol together with cosmetic ingredients. In preferred embodiments the hair styling stick contains from 30 to 55 percent by weight of one or more polyethylene glycols with a molecular weight of from 2500 to 5000 g/mol; from 15 to 35 percent by weight of one or more polyethylene glycols with a molecular weight of from 850 to 1600 g/mol, from 15 to 35 percent by weight of one or more liquid polyethylene glycols with a molecular weight of from 570 to 800 g/mol and additional cosmetic ingredients, as needed. The additional cosmetic ingredients can include an aqueous or organic solvent, emulsifier, perfume or fragrance, dye, preservative and/or pearlescence-imparting agent.

Abstract: Compositions and methods for delivering active agents to the skin of a subject, including a polymer, an active ingredient and a solvent are disclosed, the compositions being capable of delivery by rolling, spreading, aerosol or in droplets and of forming a film in contact with the skin.

Abstract: Poly(ethylene glycol) carbamate derivatives useful as water-soluble prodrugs are disclosed. These degradable poly(ethylene glycol) carbamate derivatives also have potential applications in controlled hydrolytic degradation of hydrogels. In such degradable hydrogels, drugs may be trapped in the gel and released by diffusion as the gel degrades, or they may be covalently bound through hydrolyzable carbamate linkages. Hydrolysis of these carbamate linkages releases the drug at a controllable rate as the gel degrades.

Abstract: The present invention relates to a method for treating obesity, a method for reducing the absorption of dietary fat, and a method for treating hypertriglyceridemia in a patient and to particular polymers for use in the methods or in a manufacture of a medicament. The methods comprise the step of orally administering to a mammal, such as a human, a therapeutically effective amount of one or more fat-binding polymers. The administration of the fat-binding polymer of the invention facilitates the removal of fat from the body prior to digestion, with minimal side effects and low toxicity. In a preferred embodiment, the one or more fat-binding polymers are administered in combination with one or more lipase inhibitors, for example, lipstatin and tetrahydrolipstatin.

Abstract: A composition including 2-hexyl cyanoacrylate and goal is useful in treating arteriovenous malformations (AVMs) and other body lumens to be blocked.

Abstract: Pharmaceutical compositions that have excellent storage stability even though they include a active component that is susceptible to degradation in an acidic environment are disclosed. The stabilized pharmaceutical composition of the invention includes a ring-opened 7-substituted-3,5-dihydroxyheptanoic or a ring-opened 7-substituted-3,5-dihydroxyheptenoic acid, or a pharmaceutically acceptable salt thereof, as an active component and a stabilizing effective amount of at least one amido-group containing polymeric compound or at least one amino-group containing polymeric compound, or combination thereof; wherein the stabilized pharmaceutical composition does not contain a stabilizing effective amount of another stabilizer or a combination of other stabilizers.